Readmission Rates After Major Surgery High for Older Adults
By Lori Solomon HealthDay Reporter
TUESDAY, March 19, 2024 -- Older adults face high rates of readmission within 180 days of major surgery, according to a study published online Feb. 28 in JAMA Network Open.
Yi Wang, Ph.D., from Yale University in New Haven, Connecticut, and colleagues estimate the number of hospital readmissions within 30 and 180 days after major surgery among community-living U.S. residents aged 65 years and older. The analysis included 1,477 participants in the National Health and Aging Trends Study (1,780 major surgeries).
The researchers found that the weighted rates of hospital readmission were 11.6 percent for 30 days and 27.6 percent for 180 days. Within 180 days, the highest readmission rates were seen among participants aged 90 years and older (36.8 percent), those undergoing vascular surgery (45.8 percent), and persons with frailty (36.9 percent) or probable dementia (39.0 percent). With death as a competing risk in age- and sex-adjusted models, the hazard ratios for hospital readmission within 180 days were 2.29 for frailty and 1.58 for probable dementia.
"These readmission rates are high," co-senior author Robert D. Becher, M.D., also from the Yale School of Medicine, said in a statement. "This study adds to our understanding of what it means to recover from major surgery as an older person."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted March 2024
Read this next
AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours
WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
Patient–Primary Care Provider Language Concordance Tied to Better Outcomes
TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.